Dr Reddy’s Laboratories Share Price Target 2026: Analyst Consensus, Bull Case & Bear Case

Mon Apr 13 2026

Dr Reddy’s Laboratories (Pharmaceuticals) is trading at Rs 1,160 as of April 2026, with a 52-week range from Rs 1,000 to Rs 1,380 and a 1-year return of -10%. The analyst consensus 12-month Dr Reddy’s Laboratories share price target stands at Rs 1,350-1,600 — implying meaningful potential movement from current levels.

Whether you are a long-term holder reassessing your position or a new investor evaluating entry levels, understanding where analysts see Dr Reddy’s Laboratories heading over the next 12-24 months requires looking beyond the CMP. This article covers the key catalysts and risks, technical levels, institutional positioning, and a structured breakdown of the short-term, 12-month, and long-term Dr Reddy’s Laboratories share price targets.

Click Here — Get Free Investment Predictions on Univest.

Table of Contents

Dr Reddy’s Laboratories Key Data — CMP, Valuation, Fundamentals

Parameter	Value
CMP (April 2026)	Rs 1,160
52-Week High	Rs 1,380
52-Week Low	Rs 1,000
1-Year Return	-10%
Trailing P/E	18x
Price-to-Book	2.8x
Market Cap	Rs 97,000 Cr
Sector	Pharmaceuticals
Promoter Holding	26.7%
FII Holding	20.4%
DII Holding	22.6%

Track live Dr Reddy’s Laboratories fundamentals and analyst ratings on the Univest Screener.

Dr Reddy’s Laboratories Share Price Targets — Short-Term, 12-Month & Long-Term

Access premium analyst research on Univest.

Scenario	Target	Basis
Short-Term (3-6M)	Rs 1,350	Technical support; near-term catalyst
12-Month Consensus	Rs 1,350-1,600	Analyst consensus based on current fundamentals
Bull Case (FY28)	Rs 2,000	Full execution of growth catalysts below
Bear Case	Rs 950	Materialisation of key risks below

Bull Case — What Has to Go Right for Dr Reddy’s Laboratories

1. Biosimilar portfolio (Rituximab, Bevacizumab, Filgrastim) ramping in US and Europe

$200M+ annualised revenue growing 30%

2. Siromus (Sirolimus) approved for US

next phase of complex generics pipeline

3. India branded generics growing 12%

Dr Reddy’s is one of India’s 10 largest pharma companies by prescription market share

4. EBITDA margin above 25% as biosimilar mix improves

highest among large-cap Indian pharma peers

5. At 18x P/E

among the cheapest large-cap quality pharma stocks

Bear Case — Key Risks to the Dr Reddy’s Laboratories Share Price Target

Risk 1: US generic price erosion continuing to pressure base business revenue

US generic price erosion continuing to pressure base business revenue

Risk 2: Biosimilar market becoming competitive as Biocon, Mylan, and Pfizer all compete in same molecules

Biosimilar market becoming competitive as Biocon, Mylan, and Pfizer all compete in same molecules

Institutional Sentiment and Technical Analysis

Dr Reddy’s Laboratories has 20.4% FII holding and 22.6% DII holding. High FII ownership of 20.4% means the stock is sensitive to global risk-off events — FII selling can be disproportionate to any specific negative news.

Technically, Dr Reddy’s Laboratories is trading at Rs 1,160 against a 52-week range of Rs 1,000 to Rs 1,380. The -10% 1-year return positions the stock in negative territory — creating both risk of further downside and opportunity for mean reversion. The 12-month analyst target of Rs 1,350-1,600 implies the stock is expected to recover meaningfully from current depressed levels.

Download the Univest iOS App or Univest Android App for real-time research and analyst updates.

Conclusion — Our View on ${name} Share Price Target

Dr Reddy’s at Rs 1,160 and 18x P/E is the most attractively valued large-cap pharma stock in India. The biosimilar platform (Rituximab, Bevacizumab, Filgrastim) is at an inflection point, with revenue growing 30%+ from a meaningful base. At this valuation, the risk-reward is strongly favourable. 12-month target of Rs 1,350-1,600 implies 16-38% upside.

Subscribe to Univest Pro for SEBI-registered analyst recommendations — entry, target, stop-loss.

Frequently Asked Questions

Q1. What is Dr Reddy’s Laboratories share price target 2026?

Dr Reddy’s Laboratories share price target for 2026 is Rs 1,350-1,600 based on analyst consensus. The bull case target is Rs 2,000 and the bear case is Rs 950. These are analyst estimates, not guaranteed returns.

Q2. Is Dr Reddy’s Laboratories a good buy now?

Dr Reddy’s Laboratories is trading at Rs 1,160 against a 52-week range of Rs 1,000 to Rs 1,380. Analyst consensus target of Rs 1,350-1,600 implies upside from current levels. Consult a SEBI-registered financial advisor before investing.

Q3. What is Dr Reddy’s Laboratories’s current valuation?

Dr Reddy’s Laboratories trades at a trailing P/E of 18x and price-to-book of 2.8x with a market capitalisation of Rs 97,000 Cr. The stock’s valuation relative to earnings growth determines the appropriate entry point.

Q4. What are the key risks for Dr Reddy’s Laboratories?

Key risks for Dr Reddy’s Laboratories include the factors outlined in the Bear Case section of this article. US generic price erosion continuing to pressure base business revenue is the primary near-term risk to watch.

Q5. Where can I track Dr Reddy’s Laboratories share price live?

Track Dr Reddy’s Laboratories share price live, quarterly results, FII/DII activity, and analyst ratings on the Univest Screener at univest.in/screeners. Download the Univest iOS or Android App for daily research.

Disclaimer: Investment in the share market is subject to risk. This article is for informational and educational purposes only and does not constitute investment advice. All analyst targets are estimates and may change. Verify all numbers before investing. Consult a SEBI-registered financial advisor before making any investment decisions.

For more stock research, visit Univest Blogs.